Sexual differentiation and reproductive development of female rat offspring after paternal exposure to the anti-tumor pharmaceutical cisplatin

Autor(es)

Villela e Silva, Patricia ^[1] ; da Silva, Raquel Frenedoso ^[1] ; Borges, Cibele dos Santos ^[1] ; Cavariani, Marilia Martins ^[1] ; Diniz de Almeida Francia, Camila Contin ^[2] ; Barbosa Junior, Fernando ^[3] ; Kempinas, Wilma De Grava ^[1]

Afiliação do(s) autor(es)

^[1] UNESP Univ Estadual Paulista, Inst Biosci Botucatu, Dept Morphol, BR-18618689 Botucatu, SP - Brazil

^[2] UNESP Univ Estadual Paulista, Inst Biosci Botucatu, Dept Anat, BR-18618689 Botucatu, SP - Brazil

^[3] Univ Sao Paulo, Fac Pharmaceut Sci Ribeirao Preto, Dept Clin Toxicol & Bromatol Anal, BR-14049 Ribeirao Preto, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: REPRODUCTIVE TOXICOLOGY; v. 60, p. 112-122, APR 2016.
• Citações Web of Science: 3

Resumo

Cisplatin (CP) is used to treat a number of cancers, including testicular cancer. Studies indicate that CP-treatment can impair spermatogenesis in humans and rodents by germ cell DNA binding, through different modes of action. CP-paternal exposure resulted in adverse effects in F1 male offspring. In this study, F1 female offspring was assessed for reproductive development after CP-paternal exposure. Peripubertal male rats, treated with 1 mg/Kg/day of CP or vehicle for 3 weeks, were mated with unexposed females. F1 female offspring of CP-treated fathers showed a decrease in fetal ovary germ cells, in estrous cycle length and FSH levels, and an increase in the percentage of antral follicles in adults. Based on our previous results and the findings of the present work we concluded that CP-paternal exposure leads to adverse effects on rat male and female reproductive development, raising concern, in humans, for children born to men exposed to CP. (C) 2016 Elsevier Inc. All rights reserved. (AU)

• Processo FAPESP: 12/12970-1 - Avaliação do desenvolvimento do sistema genital e da função reprodutiva da prole feminina de ratos Wistar expostos à cisplatina durante a peri-puberdade.
• Beneficiário: Patrícia Villela e Silva
• Modalidade de apoio: Bolsas no Brasil - Mestrado